Acute Meyeloid Lukemia. C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue - C92.0Acute myeloblastic leukaemia [AML]
Conditions
Interventions
Intervention 1: Intervention group patients after receiving one or two courses of induction chemotherapy (cytarabine+daunorubicin) and after achieving complete remission, are treated with high dose ar
Sponsors
Pooyesh Darou Biopharmaceutical Company
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Denovo AML Age 15-65 Achieved complete remission after induction chemotherapy Received high dose of Cytarabine in consolidation chemotherapy
Exclusion criteria
Exclusion criteria: Secondary AML ECOG performance status=3 Have any effective disease (such as cardiovascular disease, renal disease, liver disease, pulmonary disease, diabetes, high blood pressure etc.) or receiving drugs and continuous treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time of reaching ANC above 1500/ul by using PD-lasta. Timepoint: Patient daily absolute neutrophil count (ANC) record until ANC reaches above 1500 per microlitre. Method of measurement: Colter. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of PD-Lasta in reducing the incidence of infection after chemotherapy. Timepoint: From day 14 after chemotherapy. Method of measurement: Clinical evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohsen Esfandbod
Tehran University of Medical Sciences
Outcome results
None listed